thank you.
We have posted comments on its acquisitions. On earnings, EPS of 12c beat estimates of 8.5%; Revenue $527M missed estimates of $544M. EBITDA of $33.2M missed estimates by 6%. Despite the miss, Raymond James still raised its target price. Revenue fell 7.9%. EBITDA rose 0.9%. Lower pricing was the main factor but the company still claimed 'strong gross margin performance'. The stock saw some profit taking on the news. Not great performance, but not really a disaster. The stock is priced well, but its leveraged balance sheet would still be our biggest concern here.